Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

NCT06361589 · clinicaltrials.gov ↗

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

ALK-positive Non-small Cell Lung Cancer
Real World Study

Interventions

DRUG: Lorlatinib

Sponsor

Sichuan Cancer Hospital and Research Institute